摘要
目的探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)中EGFR基因突变与切除修复交叉互补基因1(excision repair cross-complementation group 1,ERCC1)、Ki-67蛋白表达及其临床意义。方法采用DNA测序法检测EGFR基因突变,免疫组化En Vision法检测ERCC1、Ki-67蛋白表达,分析与临床病理特征的关系。结果 EGFR基因突变率为49.1%(143/291),多见于女性、不吸烟、腺癌患者。EGFR基因突变在腺癌的不同亚型中差异有显著性(P=0.008);EGFR基因突变组肿瘤直径的中位数小于野生型组(P=0.020);EGFR基因突变与患者年龄、淋巴结有无癌转移无相关性(P>0.050);鳞状细胞癌中ERCC1阳性率高于腺癌(P=0.039)。Ki-67表达与肺癌分化程度有关,低分化高于高、中分化(P=0.010);ERCC1、Ki-67表达与EGFR基因突变无相关性(P>0.050)。结论 EGFR基因突变与NSCLC患者性别、组织学类型、分化程度等相关,存在多种突变。EGFR基因突变与ERCC1、Ki-67表达无相关性。
Purpose To study the status of EGFR mutations and the expression of excision repair cross-complementation group 1 ( ER-CC1) and Ki-67 protein in patients with non-small cell lung cancer (NSCLC) and to examine the relationship between their expression and clinicopathologic features. Methods EGFR mutations were analyzed with DNA sequencing, and the expression of ERCC1 and Ki-67 protein was examined by immunohistochemistry EnVision. The relationship of EGFR mutations with the expression of ERCC1and Ki-67 and the clinicopathological features were analyzed. Results EGFR mutations were detected in 143 (143/291, 49. 1%) of the 291 specimens. EGFR mutations were found more frequently in women, non-smokers and adenocarcinoma. The difference of EGFR muta-tion rate between the histological subtypes according to the IASLC/ATS/ERS classification of lung adenocarcinoma was significantly ( P=0. 008). The mean tumor diameter was smaller in patients with EGFR mutations than in those with wild-type EGFR (P=0. 020). EGFR mutations were not related to age, lymph node metastasis. However, EGFR mutations were not related to the expression of ER-CC1 and Ki-67 protein (P〉0. 050). Conclusions EGFR mutation is closely linked to several clinicopathological factors, such as gender, differentiation, and histological subtype. There is heterogeneity of EGFR mutation in patients with NSCLC. EGFR mutations were not related to the expression of ERCC1 and Ki-67 protein.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2015年第7期759-763,共5页
Chinese Journal of Clinical and Experimental Pathology
基金
863重点项目计划(2011AA02A110)